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Nonstandard Abbreviations and Acronyms 
EB  embryoid bodies 
FOXO1A Forkhead box O transcription factor 1A 
hESC;EC  human embryonic stem cell;derived endothelial cells 
PI3K  phosphatidylinositol 3;kinase 
VEGF  vascular endothelial growth factor 
 
Abstract 
Vascular derivatives of human embryonic stem cells (hESC) are being developed as sources of tissue;
specific cells for organ regeneration. However, identity of developmental pathways that modulate the 
specification of endothelial cells is not known yet. We studied PI3K;FOXO1A pathways during 
differentiation of hESC towards endothelial lineage and on proliferation, maturation and cell death of 
hESC;derived endothelial cells (hESC;EC). During differentiation of hESC, expression of FOXO1A 
transcription factor was linked to the expression of a cluster of angiogenesis; and vascular remodelling;
related genes. PI3K inhibitor LY294002 activated FOXO1A and induced formation of CD31+ hESC;EC. 
In contrast, differentiating hESC with silenced FOXO1A by siRNA showed lower mRNA levels of CD31 
and angiopoietin2. LY294002 decreased proliferative activity of purified hESC;EC, whilst FOXO1A 
siRNA increased their proliferation. LY294002 inhibits migration and tube formation of hESC;EC; in 
contrast, FOXO1A siRNA increased in vitro tube formation activity of hESC;EC. After in vivo 
conditioning of cells in athymic nude rats, cells retain their low FOXO1A expression levels. 
PI3K/FOXO1A pathway is important for function and survival of hESC;EC as well as in the regulation of 
endothelial cell fate. Understanding these properties of hESC;EC may help in future applications for 
treatment of injured organs. 
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Introduction 
Vascularisation of ischemic or engineered tissues is indispensable for cell viability, survival and good 
functional integration of cells following transplantation therapies[1]. Therapeutic angiogenesis or 
vasculogenesis with autologous cell transplantation using bone marrow;derived or circulating blood;
derived progenitor cells was shown to have beneficial effects in clinical trials [2]. However, the number 
and function of these cells might limit the efficiency of autologous stem cell therapy. Human pluripotent 
stem cells such as embryonic stem cells (hESC) could serve as future therapeutic source for vascular cell 
therapies replacing damaged tissues because of their major proliferative and differentiation potential. 
These cells are able to give rise to several cell types of the cardiovascular system such as cardiomyocytes, 
smooth muscle cells or endothelial cells [3,4]. Since the first generation of hESC;EC, several studies 
demonstrated the ability of hESC lines to differentiate towards endothelial lineage [5,6]. However, key 
signals regulating differentiation, function and survival of hESC;derived cells still need to be explored.  
Phosphatidylinositol 3;kinase (PI3K), a lipid kinase, has been shown to play an important role in 
regulating cell proliferation, adhesion, DNA repair, senescence and stemness [7]. PI3K is highly suited for 
pharmacologic intervention, which makes PI3K pathway one of the most attractive therapeutic targets in 
cancer and diabetes [8,9]. The effect of PI3K in the therapy of cardiovascular diseases has not been tested 
yet. The members of the Forkhead box O (FOXO) transcription factor family are one of the main 
downstream components of PI3K pathway [10]. FOXO transcription factors are critical proteins in the 
regulation of pluripotency of hESC and in modulation of cardiovascular development [11–13]. FOXO 
transcription factors are involved in response to oxidative stress, in cell survival, cell cycle and 
angiogenesis [14–16]. FOXO1A;deficient embryos die around embryonic day 11 because of their 
inefficient vascular and cardiac systems [17]. FOXO1A is also important in regulation of endothelial cell 
fate. Indeed, it has been found that mouse embryonic stem cell;derived endothelial cells lacking FOXO1A 
are unable to respond to vascular endothelial growth factor (VEGF), an important angiogenic growth 
factor for normal vascular development [16]. 
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The aim of our study was to examine the changes of genes related to PI3K;FOXO1A pathways, 
investigate the role of FOXO1A during differentiation of hESC towards endothelial lineage and describe 
the impact of modulation of FOXO1A on proliferation, maturation and cell death of hESC;EC. A better 
understanding of PI3K;FOXO1A;related signalling control of specification of human endothelial cells can 
provide a therapeutic advantage in cell transplantation and tissue engineering. 
 
Materials and Methods 
Human embryonic stem cell culture and differentiation towards endothelial cells 
Human embryonic stem cells (H7, Wicell Bank, Madison, WI) were maintained in feeder;free 
conditions as described previously [18]. Undifferentiated cells were plated onto Matrigel (BD Sciences);
coated 6;well plates and fed with mouse embryonic fibroblast;conditioned medium supplemented with 8 
ng/ml of recombinant human basic fibroblast growth factor (Invitrogen). Before induction of 
differentiation, spontaneously differentiated cells were removed by treatment with dispase at 37 °C for up 
to 7 min. Differentiation of hESCs towards endothelial;like cells (hESC;EC) were carried out as described 
previously [19]. Human ESC colonies were mechanically broken with a 5 ml pipette tip and were placed 
into low;attachment 6;well plates in medium containing 2% foetal calf serum (Endothelial Growth 
Medium;2, EGM2, Lonza) for 4 days to form embryoid bodies (EB). EGM2 media was prepared by 
addition of SingleQuot supplements and growth factors to EBM2 basal medium. Supplements included 
human epidermal growth factor (hEGF), gentamicin;amphotericin;B 100, R3; insulin growth factor (IGF);
1, ascorbic acid, vascular endothelial cell growth factor (VEGF), human fibroblast growth factor (hFGF);
B, heparin, and hydrocortisone. EBs were seeded on gelatine coated flasks. CD31+ cells were sorted by a 
cell sorter (BD FACSAria, BD Biosciences) from cultures 13 days after differentiation [20] and expanded 
in EGM2. For antibody titration, IgG1K;APC isotype control (R&D Systems IC002a) was used. The 
medium was changed in every 2 days. Passages between 4 and 9 were used for experiments. Human 
umbilical cord vein cells (HUVEC), used as control endothelial cells, were a gift from Caroline Wheeler;
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Jones (Royal Veterinary College, London) and were maintained in EGM2 and used between passages 3 
and 11. Human coronary arterial endothelial cells (HCAEC) were purchased from Lonza.  
 
Cell treatments with PI3K inhibitor, FOXO1A siRNA and FOXO1A plasmid 
Human ESC were treated with LY294002 (10 µM, Sigma, medium changed every 24 hours) 
during endothelial differentiation. Dimethyl sulfoxide was used as control in the same concentration. 
Human ESC;EC were plated onto 0.5% gelatinised 96;well plates at a density of 10000 cells/well and 
grown to confluence. The CD31+ cells were treated with LY294002 (10 µM) for 24 hours. H2O2 was used 
as a stable reactive oxygen species for induction of cell death in three different concentrations (high dose, 
900 µM; medium dose, 300 µM; low dose, 100 µM) for 12 hours. For FOXO1A small interfering RNA 
(siRNA) knockdown on differentiating hESC as well as purified hESC;EC cultures, FOXO1A Flexitube 
siRNA Premix (10 nM, 6h and 24h, Qiagen) was performed as per manufacturer’s instruction. Scrambled, 
non;targeting (NT) siRNA (10 nM, Qiagen) was used as negative control. Differentiating hESC cultures 
were re;transfected every 48 hours to maintain the effects of siRNA. 
Transfection of hESC;EC with plasmids encoding FOXO1A;eGFP [21] or pmaxGFP (Lonza) 
used as DNA control was carried out by electroporation. Briefly, 106 hESC;EC were resuspended in 400 
Vl of EGM2 medium (Lonza) containing 5µg plasmid DNA, electroporated on a Gene Pulser Xcell Total 
modular electroporation apparatus (BioRad) using time constant program (200v, 25ms). Assessment of 
overexpression efficiency by TaqMan real time PCR and experiments were performed 48 hours later. 
 
Matrigel tube-formation assay 
Matrigel (BD Biosciences) was thawed on ice overnight and 24;well plates were coated with 200 
µl Matrigel per well and then allowed to solidify at 37°C for 30 minutes. Control, LY294002, NT or 
FOXO siRNA;pretreated hESC;EC (50000 cells/well) were plated onto Matrigel and cultures were 
photographed and quantitated after 24 hours of incubation. 
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Angiogenesis and soluble receptor proteome profiling 
Angiogenesis proteome profiling was carried out with Proteome Profiler Human Angiogenesis 
Array Kit (RnD Systems, ARY007). The human soluble receptor proteome profiling array was performed 
with Human Soluble Receptor Array Kit Hematopoietic Panel (RnD Systems, ARY011). The sample 
preparation and experimental setup followed the product catalogue guide. Proteome profile of hESC;ECs 
was compared with control HCAEC. Pixel densities of the x;ray films were analysed by ImageJ software. 
 
Colony formation assay 
Cultures of hESC;EC were dissected into single cells, filtered through a 40;Vm cell strainer (BD Falcon), 
and 5,000 isolated cells were plated on gelatin into each well of 96;well plates. Cells were treated with 
LY294002 or FOXO1A siRNA or overexpressed with FOXO1A;eGFP. Plates were stained for Hoechst at 
day 0, 1, 2, and 3. The colony formation activity and the number of nuclei per colony were assessed by 
using a Colony Formation BioApplication on Cellomics platform. 
 
In vivo transplantation by Matrigel plug assay 
Human ESC;EC and HUVEC were cultured in vitro and 106 cells/plug were injected 
subcutaneously into 3;month;old athymic nude rats (Crl:NIH;Foxn1rnu, Charles River) in a suspension of 
Matrigel (250µl), heparin (64U/ml), recombinant murine basic FGF (80ng/ml, R&D Systems) and EGM2 
(70µl). Matrigel suspension without cells was used as control. The injection sites were four parts of the 
abdominal subcutaneous region. After 3 weeks, rats were sacrificed; plugs were harvested and stored at ;
80°C for immunohistochemistry or RNA isolation. The experimental protocols were approved by The 
Animal Use and Care Committee of Semmelweis University Budapest. The investigation conforms to the 
Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health. 
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Immunocytochemistry and ac-LDL-uptake 
Endothelial cells were plated into 96;well plates and after treatments cells were fixed with 4% 
paraformaldehyde for 10 minutes at room temperature (RT), permeabilized with 0.2% Triton X;100 for 10 
minutes and blocked with 4% FBS in PBS for 1 hour at RT. Cells were stained for immunocytochemistry 
for CD31 (Santa Cruz, 1:100), FOXO1A (Millipore, 1:200), ve;cadherin (Abcam, 1:100), CD45 (Abcam, 
1:100) and Ki67 (Abcam, 1:100) using rabbit anti;human polyclonal antibodies for 1 hour at RT. Primary 
antibodies were detected with Alexa 488; and Alexa 546;conjugated secondary antibodies (Life 
Technologies, 1:400) for 45 minutes at RT. Hoechst 33342 (Life Technologies, 1:1000) was used for 
staining nucleus. For confirmation of ve;cadherin, cells were transfected with ve;cadherin;driven eGFP 
construct [22] and visualised confocal microscopy after 2 days. 
For further identifying endothelial phenotype, cells were incubated with 10 µg/ml DiI;labelled acetylated 
low;density lipoprotein (DiI;Ac;LDL, Invitrogen) contained EGM;2 medium for 4 hours at 37°C, then 
washed twice with EGM;2 medium and observed by fluorescent microscope (Zeiss Axio Observer Z1). 
For the measurement of cytoplasm to nuclear translocation of FOXO1A [23], hESC were stained with 
anti;FOXO1A antibody and plates were scanned using automated high content screening reader Cellomics 
VTi HCS ArrayScanner (Thermo Scientific, Pittsburgh, USA). The arrayscanner is an automated 
fluorescence microscope that provides comprehensive data on the spatial and temporal distribution of 
fluorescence intensities in culture plates. Hoechst staining was used to define the nucleus [24]. Binary 
image masks were created also for FOXO1A staining to define regions of interest for analysis. Mean 
nuclear;cytosolic intensities of FOXO1A were measured and calculated using Compartmental Analysis 
Bioapplication in at least 1000 cells/well across up to 49 fields/well of a 96 well plate. Hoechst and 
FOXO1A fluorescence were captured using sequential acquisition to give separate image files for each. 
Some wells were treated with secondary antibody to establish background autofluorescence. 
Representative images are shown in Supplementary Fig. S1. 
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For live imaging for measuring parameters of cell death, supernatant was removed, and hESC;EC and 
HUVEC were stained with TOTO;1 or TO;PRO3 (Life Technologies, 1:1000) and Hoechst 33342 (Life 
Technologies, 1:1000) for 10 minutes in EGM2 medium. Fresh serum;free medium was added after 1 
hour. Change in nuclear morphology is a hallmark of the final stage in cell death. Nuclear events were 
recorded as additional toxicity readouts regardless of the cell death pathway involved.  
 
Real time PCR 
Cells were lysed in TriReagent (Invitrogen) and total RNA was isolated using the RNeasy Mini 
kit (Qiagen). To generate single;stranded cDNA, High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) was used and for quantifying Oct4, FOXO1A, CD31, Tie2, and angiopoietin2 
(Ang2) real;time PCR analyses were performed with TaqMan Gene Expression Assays (Oct4: 
Hs00999634_gH; FOXO1A: Hs00231106_m1, CD31: Hs00169777_m1; Ang2: Hs01048043_m1, Tie2: 
Tie2: Hs00945142_m1, Applied Biosystems). Human GAPDH Endogenous Control (FAM/MGB probe, 
Applied Biosystems) was used as a housekeeping control. The PCR was performed with Rotor;Gene 3000 
(Corbett Research) and StepOnePlus (Applied Biosystems) real;time PCR instruments and the relative 
expression was determined by XXCt method in which fold increase = 2−XXCt. 
  For the PCR array (Human PI3K;AKT Signalling RT2 Profiler PCR Array Kit, PAHS;058, SA 
Biosciences), cDNA was synthesised from 1 µg of total RNA then hybridized in a 96;well format. PCR 
array data intensity values were normalised by gene;centred z score transformation. A modified z;score 
threshold of 3.5 was used as criteria defining outliers, these samples were excluded from a rerun of the z;
statistics. By calculating the gene expression stability measure M, which is the mean pair;wise variation 
for a gene from all other tested genes, ACTB and RPL13A were accepted as being the most stable 
housekeeping ones. Normalized XCT values were derived as XCT(gene); XCT (averaged geometric mean 
between above housekeeping controls). Correlation plots and heatmaps were plotted for all samples and 
technical replicates were averaged. To reveal biologically relevant interactions for activated kinases, 
pathway analysis was performed by Ingenuity Pathways Analysis software 
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(https://analysis.ingenuity.com). Ingenuity Pathways are based on a curated database of published 
literature on gene functions and interactions. As one of the outputs Ingenuity identifies hub genes based on 
high degree of links to other genes in known pathways. 
 
Statistical analysis 
Data are expressed as mean ± sem. Experiments were carried out in triplicates. Statistical analyses 
were performed by Student’s t;test or ANOVA with Tukey post hoc test. P values less than 0.05 were 
considered statistically significant. 
 
Results 
PI3K/Akt/FOXO1A pathway during endothelial differentiation of human embryonic stem cells 
We differentiated hESC towards endothelial lineage and used FACS to isolate CD31+ cells at day 
13 after initiation of differentiation. We found that mRNA levels of OCT4, an embryonic stem cell 
marker, were gradually decreased in differentiating hESC and in differentiated hESC;derived CD31+ cells 
(Fig. 1A). Expression of CD31 and key angiogenic factor angiopoietin2 showed marked up;regulation 
during differentiation of hESC toward endothelial cells; however, it did not bring expression levels to 
those of HUVEC used as control endothelial cell (Fig. 1A). Levels of the angiopoietin1 receptor Tie2 
showed only modest increase during the differentiation (Fig. 1A). To investigate the changes of genes 
related to PI3K pathway during endothelial differentiation of hESC, we analysed the expressions of main 
PI3K genes using a quantitative PCR array. Undifferentiated and differentiating hESC (embryoid bodies, 
EB, at day 4), and sorted CD31+ hESC;EC showed different expression levels of most genes tested in this 
pathway (Fig. 1B). Undifferentiated hESC expressed high mRNA levels of FOXO1A transcription factor; 
this critical downstream element of PI3K pathway was strongly down;regulated during differentiation. 
When compared to HUVEC, we found matching expression levels of most of the PI3K pathway elements 
in hESC;EC (Fig. 1B, bar graph). We also found that mRNA levels of PI3K;partners such as BTK and 
CD14 were higher, whereas PIK3R1 and PDGFRA were lower in hESC;EC than those in HUVEC (Fig. 
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1BC). To infer gene networks from expression profile of hESC;EC, Ingenuity pathway network analysis 
was performed. It suggested that FOXO1A expression is specifically linked to an indispensable cluster of 
angiogenesis; and vascular remodelling;related genes, including VEGF2 as well as PDK1, cdc42, and 
PRKCB1 (Fig. 1D). Furthermore, analysis suggests that VEGF may signal through a PTEN/PDGFRA 
pathway and modulate FOXO1A (Fig. 1D). 
 
PI3K/FOXO1A pathway modulates endothelial differentiation of human embryonic stem cells 
Next we targeted PI3K/FOXO1A pathway to directly assess its role in endothelial differentiation. 
Administration of LY294002 during differentiation increased mRNA levels of CD31 and angiopoietin2 in 
differentiating hESC (Fig. 2AB). Tie2 mRNA levels were downregulated in response to LY294002 (Fig. 
2C). Cells treated with FOXO siRNA showed however lower mRNA levels of CD31 (p=0.07) and 
angiopoietin2 (p<0.001) as compared with non;targeting siRNA group (Fig. 2AB). Treatment with FOXO 
siRNA resulted in increased mRNA levels of Tie2 (Fig. 2C). FOXO1A mRNA levels were lower after 
siRNA treatment on hESC (Supplementary Fig. S2B). Use of PI3K inhibitor/FOXO1A activator 
LY294002 tended to increase the percentage of newly formed CD31+ hESC;EC in the presence of EGM2 
medium, containing endothelial growth factors (LY294002: 0.62±0.04% vs. 0.24±0.1% of control 
differentiating hESC culture; Fig. 2D). LY294002 resulted in higher FOXO1A mRNA levels of 
differentiating hESC (Supplementary Fig. S2A). By contrast, silencing of FOXO1A by siRNA during 
differentiation had no influence on the percentage of CD31+ cells (Fig. 2D).  
 
Modulation of PI3K/FOXO1A signalling pathway in sorted hESC-EC  
Cultures of differentiated CD31+ hESC;EC were highly proliferative and showed specific 
endothelial characteristics such as cobblestone morphology, evidence of DiI;labelled acetylated LDL 
uptake, and positive expression ve;cadherin;eGFP and staining for ve;cadherin (Supplementary Fig. 
S3ABCD). As assessed by proteome profiler, protein levels of angiogenic and endothelial factors showed 
similarities in hESC;EC and control adult HCAEC (Supplementary Fig. S4E). Human ESC;EC had low or 
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not detectable levels of haematopoietic markers (Supplementary Fig. S4F). As shown by high content 
microscopy, hESC;EC did not express the hematopoietic progenitor cell marker CD45 (Supplementary 
Fig. S4G).  
To test the effects of PI3K/FOXO1A modulation in hESC;EC, we treated cells with LY294002 or 
FOXO1A siRNA. Nuclear translocation and mRNA levels of FOXO1A were markedly increased in 
hESC;EC in response to LY294002 (Supplementary Fig. S2CD). In contrast, silencing of FOXO1A with 
siRNA decreased both mRNA and nuclear translocation levels of FOXO1A as early as after 6 hours 
treatment in hESC;EC (Supplementary Fig. S2EF). Similarly to differentiating hESC, mRNA levels of 
CD31 tended to increase in response to LY294002 and decreased in cells with FOXO siRNA (Fig. 3AD). 
Angiopoietin2 mRNA were also increased in response to LY294002 in hESC;EC; on the other hand, 
FOXO siRNA resulted in lower mRNA levels of angiopoietin2 (Fig. 3BE). The mRNA levels of the Tie2 
were inversely regulated as compared to angiopoietin2 (Fig.3CF).  
Proliferative activity of sorted hESC;EC cultures were assessed by Ki67 marker and colony 
formation. Percentage of Ki67+ cells and colony formation activity after 3 days were significantly 
decreased in response to LY294002 (Fig. 3GHI); in contrast, further downregulation of FOXO1A 
expression by siRNA treatment resulted in a modest increase in the ratio of Ki67+ cells (p<0.05) with no 
effect on cell number (Fig. 3GHJ). Overexpression of FOXO1A alone did not change the ratio of Ki67;
positive cells and colony formation in hESC;EC population (Supplementary Fig. S4AB). This may 
suggest distinct role of PI3K/FOXO1A pathway in cell generation during hESC differentiation as 
compared to those in a later stage in sorted hESC;EC.  
 
Targeting PI3K/FOXO1A pathway alters hESC-EC viability 
Next we tested the role of PI3K/FOXO1A pathway on viability and cell survival of hESC;EC. As 
assessed by high content microscopy, oxidative stress induced by H2O2 activated FOXO1A as shown by 
its increased nuclear density (Supplementary Fig. S5AB). Using H2O2 as a danger signal caused necrosis 
and nuclear remodelling (expressed as decreased nuclear size) in a dose;dependent manner in hESC;EC 
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(Supplementary Fig. S5CD). Silencing of FOXO1A by siRNA had no effect on levels of necrosis marker 
TOTO1 or nuclear remodelling in hESC;EC (p<0.05, Supplementary Fig. S5CD). Pre;treatment with 
LY294002 increased the pro;necrotic effects of H2O2 (at a dose of 600 µM, P<0.001) in hESC;EC. 
Overexpression of FOXO1A resulted in higher levels of necrosis compared to those in control plasmid;
transfected hESC;EC (Supplementary Fig. S4CDE). The level of necrosis in response to H2O2 was not 
modulated by FOXO1A overexpression. Using LY294002 without external danger signal (such as H2O2) 
had no effect on viability of hESC;EC (Supplementary Fig. S5CD).  
 
PI3K/FOXO1A pathway modulates angiogenic activity of hESC-EC 
In vitro tube formation assay revealed that LY294002 inhibits hESC;EC migration and formation 
of tubes (Fig. 4ABCD). On the other hand, silencing of FOXO1A by siRNA markedly increased in vitro 
tube formation activity of hESC;EC as shown by total tube length and node count (p<0.001, Fig. 4AEFG). 
Overexpression of FOXO1A did not alter tube formation activity of hESC;EC (Supplementary Fig. 
S4FGH). To test the viability and maturation of hESC;EC with low FOXO1A levels also in vivo, cell 
were transplanted into athymic nude rats. Human ESC;EC showed engraftment (Fig. 4H); after 21 days 
conditioning of cells, angiopoietin2 and tie2 mRNA levels were markedly increased in hESC;EC similarly 
to those in control HUVEC (Fig. 4JK). However, hESC;EC retain their low FOXO1A expression levels 
during the incubation period (Fig. 4I) whereas FOXO1A mRNA levels are further increased in HUVEC.  
 
Discussion 
The underlying intracellular signalling mechanisms in the generation and function of human 
pluripotent stem cell;derived endothelial cells have not been described in details. In this study we showed 
that PI3K pathway is one of the key intracellular signalling mechanisms which have wide;ranging effects 
on endothelial differentiation of hESC as well as cell death, proliferation and angiogenic activity of 
generated hESC;EC partially through FOXO1A transcription factor (Fig. 5). 
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The role of PI3K in generating new endothelial cells was supported by our observation that hESC 
differentiation towards endothelial lineage is accompanied with marked changes in expression of most of 
the genes related to PI3K/FOXO1A pathways. FOXO1A was shown to be the most abundant FOXO 
member at mRNA levels in undifferentiated hESC colonies and alteration of FOXO1A causes different 
expression of pluripotency genes in hESC indicating FOXO1A has a critical role in the regulation of 
hESC fate [11]. Indeed, here we showed that high FOXO1A expression was significantly downregulated 
during embryoid body formation and further differentiation into endothelial cells. Changes in expression 
also correlated with loss of pluripotency markers. By using a gene expression array of PI3K pathway 
elements, Ingenuity pathway analysis with a curated database and subsequent clustering as an exploratory 
tool, we identified connections between FOXO1A and VEGF as well as various further angiogenic 
factors. Time development during differentiation modulated the expression of angiogenic factors clustered 
with FOXO1A such as PDK1 which play a role in vascular remodelling and endothelial differentiation 
[25]; cdc42, known to mediate tubulogenesis [26]; protein kinase C beta, being a stimulus for endothelial 
proliferation [27]; and activation of Rheb/mTOR for endothelial cell transformation [28]. As a potential 
result of these interactions, we found that inhibition of PI3K and consequent re;activation of FOXO1A by 
LY294002 resulted in an increased number of newly formed endothelial cells. Higher FOXO1A levels 
were accompanied with increasing CD31 and angiopoietin2 expression levels as well as an inverse 
downregulation in tie2 levels in the differentiating culture. This suggests an indirect link between 
FOXO1A levels and the propensity of differentiating hESC towards endothelial lineage. The fact however 
that the control endothelial HUVEC expressed FOXO1A at a higher level than hESC;EC suggests that 
post;transcriptional control of FOXO1A is more important in HUVEC than those in hESC;EC. 
The role of FOXO1A in endothelial development was further evidenced by siRNA silencing 
experiments. Directly targeting FOXO1A factor decreased expression of endothelial cell markers and 
angiogenesis genes. This also suggests that culture medium containing VEGF and other endothelial 
cytokines may be potent stimulus for endothelial differentiation where PI3K/FOXO1A pathway, at least in 
part, mediates these signals. This is similar to other studies, where VEGF was shown to increase the yield 
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of adult endothelial cells in differentiated hESC culture [29] and can also favour endothelial cell survival, 
proliferation and cell cycle progression via the PI3K/Akt pathway during tissue regeneration and disease 
[30,31]. 
Intact PI3K signalling as well as low but detectable FOXO1A levels may be prerequisite for 
endothelial differentiation. However, our data suggest a different regulatory role for PI3K/FOXO1A in 
differentiating ESC and ESC;derived endothelial cells where FOXO1A has a mainly inhibitory feedback 
signal. We characterized the temporal expression of FOXO1A and angiopoietin2, one of the FOXO1A 
target genes [32–34] and related to angiogenesis and vascular remodelling, during in vivo differentiation 
and maturation of hESC;EC. Three weeks after transplantation of hESC;EC into athymic nude rats, cells 
showed engraftment and were detectable with histology. As opposed to HUVEC, we detected high 
angiopoietin2 and tie2 expressions, with no significant change in FOXO1A levels in hESC;EC. In vitro 
differentiation of hESC generated a unique endothelial cell type, where FOXO1A levels are significantly 
lower than those in control HUVEC, endothelial cells derived from human umbilical cord vein. This may 
suggest that these cells retain low FOXO1A levels and a controllable angiogenic activity even after in 
vivo conditioning. On contrary, we found that activation of FOXO1A by LY294002 blocked tube 
formation in culture. This activity may be further modulated by the component that inhibition of PI3K and 
consequent activation of FOXO1A by LY294002 was also found to block cell proliferation of hESC;EC. 
FOXO proteins were shown to be involved in response to oxidative stress, in regulation of 
apoptosis and cell survival [14–16]. In line with these reports, here we showed that FOXO1A mediates 
danger signals such as oxidative stress by H2O2 in hESC;EC. Indeed, activation of FOXO1A nuclear 
translocation by H2O2 was accompanied with cell loss, necrosis and nuclear remodelling in a dose;
dependent manner. Furthermore, overexpression of FOXO1A construct showed direct pro;necrotic effects 
and cell loss in hESC;EC cultures. This may suggest that FOXO1A can act as one of the downstream 
pathways for oxidative stress in hESC;EC. The fact that FOXO1A expression levels stayed low during 
cell transplantation may suggest that these cells have lower responsiveness to in vivo danger signals. On 
the other hand, we found that silencing of FOXO1A had no protective effect on stress responsiveness of 
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hESC;EC in vitro, which altogether suggests the presence of a broader regulation involving other, 
FOXO1A;independent pathways in stress;responsiveness in hESC;EC. LY294002 is one of the potent and 
specific cell;permeable inhibitor of PI3K [35]. We have found that inhibition of PI3K pathway by 
LY294002 further increased loss of hESC;EC in oxidative stress. This observation may be in line with 
earlier animal studies where development of dermal toxicity was an in vivo side effect of LY294002 in 
murine model [36]; together with low solubility and bioavailability prevented its use in clinical trials. 
However, several further compounds are being developed to inhibit different nodes of the PI3K pathway. 
These mainly PI3K/AKT/mTOR inhibitors showed no unexpected toxic effects [8]. However, no clear 
correlation between endothelial function and vascular damage, and responsiveness to PI3K/AKT/mTOR 
inhibitors has emerged from early clinical trials. It is also still unclear whether downregulation of PI3K 
signalling will be sufficient to produce a clinical response.  
In conclusion, human embryonic stem cell;derived endothelial cells represent a unique endothelial 
population, with controllable proliferative and angiogenic activities. PI3K/FOXO1A pathway is one of the 
particular key signalling elements for function and survival of hESC;EC but also in regulation of 
endothelial cell fate. We found that activated FOXO1A has various effects in hESC;EC: it mediates 
endothelial generation; on the other hand, FOXO1A, at least partly, inhibits proliferation and angiogenic 
activity, and plays a role in response to oxidative stress. To test whether using of cells along with direct 
pharmacological inhibition of FOXO to release negative feedback may be advantageous in cell therapy 
still need to be determined. 
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Figure Legends 
 Fig 1. PI3K/FOXO1A signalling;related gene expression during hESC differentiation. Human embryonic 
stem cells (hESC) were differentiated via embryoid body formation (EB) towards human embryonic stem 
cell;derived endothelial cells (hESC;EC). HUVEC were used as control endothelial cells. (A) Changes in 
mRNA levels of embryonic stem cell marker OCT4, CD31, angiogenesis markers angiopoietin2 and tie2 
at different steps of endothelial differentiation. Heat map with agglomerative clustering (B) and bar graphs 
(C) showing changes in mRNA levels of PI3K/FOXO elements during different steps of endothelial 
differentiation. Bar graphs in panel B showing differences in gene expression in HUVEC vs. those in 
hESC;EC as a baseline. Data are expressed as fold changes vs. mRNA levels in undifferentiated hESC; 
mean±SEM. Statistical significance was determined by one;way ANOVA. *p<0.05, **p<0.01, 
***p<0.01, from 3 biological replicates, one;way ANOVA with Tukey post hoc test. (D) Schematic 
diagram of Ingenuity Pathway Analysis;mapped mechanistic interactions of VEGF, PTEN, FOXO1A and 
various angiogenic modulator elements. Arrows between nodes represent direct (solid lines) and indirect 
(dashed lines) interactions between molecules as supported by information in the Ingenuity pathway 
knowledge base. ITGB1, Integrin beta;1; PRKCA, Protein kinase C alpha; PRKCZ, Protein kinase C zeta; 
PDGFRA, platelet;derived growth factor receptor alpha; PTEN, Phosphatase and tensin homolog; 
PRKCB, Protein kinase C beta; PIK3R2, phosphoinositide;3;kinase, regulatory subunit 2 beta. 
 
Fig 2. PI3K/FOXO1A signalling modulates endothelial differentiation of hESC. Bar graphs showing 
mRNA levels of CD31 (A), angiopoietin2 (B), and Tie2 (C) in differentiating hESC (EB) with LY294002 
and FOXO1A siRNA. (D) Bar graph showing CD31+ hESC;EC population in the presence of FOXO1A 
siRNA or LY294002 (10VM). mean±SEM, *p<0.05, ***p<0.001 vs. control group, 3 biological 
replicates, Student’s t;test.  
 
FIG 3. PI3K/FOXO1A signalling modulates proliferative activity of hESC;derived endothelial cells. Bar 
graphs showing changes in mRNA levels of CD31, angiopoietin2, and Tie2 in differentiated hESC;EC in 
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response to 24 hours treatment with LY294002 (ABC) or FOXO1A siRNA (DEF). (G) Representative 
picture of Ki67+ cells in hESC;EC population (magnification: x20). Changes in proliferation rate of the 
hESC;EC population (Ki67+ cells) after 24 hours (H) and in colony formation activity (IJ) in response to 
LY294002 or FOXO1A siRNA treatments for 3 days. Data are expressed as fold changes vs. percentage 
of Ki67+ cells in control hESC;EC group, mean±SEM. Fold changes in mRNA levels are shown vs. 
hESC. *p<0.05, ***p<0.001 vs. control, n=3 biological replicates. 
 
FIG 4. In vitro angiogenesis and in vivo conditioning of hESC;EC. (A) Representative Matrigel tube 
formation images of hESC;EC pre;treated with LY294002 or FOXO1A siRNA. Cells were stained with 
vital dye TMRM (red). Bar graph showing average and total tube lengths and number of formed nodes 
after LY294002 (BCD) 24 hours FOXO1A or non;targeting scrambled (NT) siRNA (FGI).***p<0.001 
vs. control, n=3 biological replicates. (E) Representative image of histological section stained with 
haematoxylin;eosin showing subcutaneously engrafted hESC;EC. (IJK) Bar graphs showing FOXO1A 
angiopoietin2 and Tie2 mRNA levels before and after in vivo conditioning of hESC;EC in Matrigel plugs 
transplanted into athymic nude rats. Data are mean±SEM (n=3;10 per group from 2 independent 
experiments (12 rats per group)). 
 
FIG 5. Mechanism of action and effects of modulation of PI3K;FOXO1A signalling pathway. Schematic 
summary shows that activation of FOXO1A with PI3K inhibitor LY294002 resulted in increased yield of 
endothelial differentiation (labelled as red panels). Proliferative and tube formation capacity decreased 
(labelled as blue panels) in the differentiated endothelial cells. Modulation of PI3K;FOXO1A signalling 
also altered angiopoietin2;tie2 system in the differentiating culture. Low FOXO1A levels increased 
proliferative activity and tube formation of the developed hESC;EC. FOXO siRNA had no effect (grey 
panels) on differentiation and cell death profile. 
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Merkely et al. Signalling via PI3K/FOXO1A Pathway Modulates Formation and Survival of 
Human Embryonic Stem Cell-Derived Endothelial Cells 
 
Supplemental Figure Legends 
Supplemental Fig. 1. Automated high content imagingbased assessments of proliferation and 
nuclear translocation of FOXO1A. The system was used to scan multiple fields from well to well and 
to acquire and analyze each of the cells in the images. Representative images show hESCEC stained 
for Hoechst (AD), Ki67 (C) and FOXO1A (F). Inlay panel in (F) shows that prior to stimulation, the 
cytoplasm is intensely red while the nucleus without FOXO1A is dark (nuclear minus cytoplasmic 
fluorescence is low). In the stimulated cell, the amount of cytoplasmic fluorescence is decreased, 
while the nuclear fluorescence markedly increases (nuclear minus cytoplasmic fluorescence is high). 
For compartmental analysis, nuclear and cytoplasmic regions of interests in each cell are also shown 
(BE). In both the nuclear and cytoplasmic areas, the intensity of fluorescence of a given protein is 
averaged throughout the measured area. White scale bars represent 20 µm. 
 
Supplemental Fig. 2. Modulation of FOXO1A expression and nuclear intensities. (A) Changes of 
FOXO1A mRNA levels after treatment with the PI3K inhibitor/FOXO1A activator LY294002 
(10<M) or FOXO1A using siRNA (B) in differentiating hESC. Changes of FOXO1A nuclear 
intensity (C) and mRNA levels (D) in hESCEC after treatment with the PI3K inhibitor/FOXO1A 
activator LY294002 (24h). Silencing of FOXO1A using siRNA caused decreased level of (E) nuclear 
intensity or (F) FOXO1A mRNA levels.**p<0.01, ***p<0.001 vs. control, n=4 biological replicates. 
 
Supplemental Fig 3. Endothelial characteristics of hESCEC. (A) Representative picture of 
cobblestone morphology of hESCEC on gelatinised plates. White scale bar represents 20 µm (B) 
CD31+ hESCEC are able to take up acetylated LDL. (C) hESCEC is positive for vecadherindriven 
GFP construct in vitro and (D) stained positive with for endothelial marker vecadherin in vivo. (E) 
Bar graph showing angiogenesis proteome profiler analysis of hESCEC. Cell lysates of hESCEC 
express wide range of angiogenesisrelated proteins. (F) Bar graph showing expression of cluster of 
Page 31 of 36
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
differentiation (CD) soluble receptors assessed by human soluble receptor proteome profiler array 
from cell culture supernatant. Data showing expression levels of hESCEC in fold changes compared 
to those in human coronary artery endothelial cells (HCAEC). Data are from two biological replicates. 
(G) Plot graph on high content analysis shows that CD45 haemopoietic marker was not expressed in 
hESCEC (red plot). Negative control is also shown (black plot). 
 
Supplemental Fig 4. Cell proliferation, cell death and in vitro angiogenesis of hESCEC with 
FOXO1A overexpression. (A) Changes in proliferation rate of the hESCEC population (Ki67+ cells, 
expressed as percentage) after 24 hours and  in colony formation activity (B) in response to 
overexpression for 3 days. (C) Changes in FOXO1A mRNA levels, ToPro3 necrosis marker (D), and 
cell number after (E) transfection (48 h) with FOXO1AeGFP or control eGFP plasmids in hESCEC. 
Angiogenic activity was assessed by node count (F), total (G) and average tube length (H) in Matrigel 
tube formation assays. Data are expressed as mean±SEM. *p<0.05, **p<0.01, ***p<0.001 vs. control 
eGFP group, oneway ANOVA with Tukey post hoc test, n=3 biological replicates. 
 
Supplemental Figure 5. Cell death of hESCderived endothelial cells is modulated by 
PI3K/FOXO1A signalling pathways. H2O2 was used in different concentrations (300, 600, 900 <M) to 
induce oxidative stress. LY294002 (10<M, 24h) and FOXO1Atargeting siRNA (24h) were used to 
modulate FOXO1A activity. (A) Representative immunocytochemistry images of FOXO1A intensity 
during cell death experiments of hESCEC (magnification 20x). Human ESCEC were stained with 
antiFOXO1A antibody and nuclei stained with Hoechst. (B) Bar graph showing changes in FOXO1A 
nuclear translocation in hESCEC pretreated with LY294002 and FOXO1A siRNA after challenging 
with H2O2. (C) Bar graph showing changes in necrotic rate measured by TOTO1 intensity of hESC
EC. (D) Changes in nuclear remodelling measuring Hoechstpositive nuclear size of hESCEC. 
***p<0.001 vs. control, n=3 biological replicates. 
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